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Abstract
Background: Randomized controlled trials (RCTs) are often complex and expensive to perform. Less than one third
achieve planned recruitment targets, follow-up can be labor-intensive, and many have limited real-world generalizability.
Designs for RCTs conducted using cohorts and routinely collected health data, including registries, electronic health
records, and administrative databases, have been proposed to address these challenges and are being rapidly adopted.
These designs, however, are relatively recent innovations, and published RCT reports often do not describe important
aspects of their methodology in a standardized way. Our objective is to extend the Consolidated Standards of Reporting
Trials (CONSORT) statement with a consensus-driven reporting guideline for RCTs using cohorts and routinely collected
health data.
Methods: The development of this CONSORT extension will consist of five phases. Phase 1 (completed) consisted of the
project launch, including fundraising, the establishment of a research team, and development of a conceptual framework.
In phase 2, a systematic review will be performed to identify publications (1) that describe methods or reporting
considerations for RCTs conducted using cohorts and routinely collected health data or (2) that are protocols or report
results from such RCTs. An initial “long list” of possible modifications to CONSORT checklist items and possible new
items for the reporting guideline will be generated based on the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) and The REporting of studies Conducted using Observational Routinely-collected health
Data (RECORD) statements. Additional possible modifications and new items will be identified based on the results of
the systematic review. Phase 3 will consist of a three-round Delphi exercise with methods and content experts to
evaluate the “long list” and generate a “short list” of key items. In phase 4, these items will serve as the basis for an in-
person consensus meeting to finalize a core set of items to be included in the reporting guideline and checklist. Phase
5 will involve drafting the checklist and elaboration-explanation documents, and dissemination and implementation of
the guideline.
Discussion: Development of this CONSORT extension will contribute to more transparent reporting of RCTs conducted
using cohorts and routinely collected health data.
Keywords: Administrative data, Cohort, CONSORT, Electronic health records, Electronic medical records, Electronic
patient records, Randomized controlled trials, RCTs, Registries, Reporting guideline, Routinely collected health data
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Background
The healthcare system is most effective when it is able to
provide evidence-based care that is informed by research
on the benefits and harms of interventions, as well as pa-
tients’ values and preferences. Randomized controlled trials
(RCTs), when well-designed and conducted, are widely
acknowledged to be the best design for providing such
evidence [1–3]. However, important concerns about RCTs
remain, including incomplete recruitment, small size, com-
plex consent procedures, limited real-world generalizability,
lack of relevant or long-term outcomes, and prohibitive
costs [4–12].
The prohibitively high costs of conventional RCTs [13]
have led to a declining number of them being conducted,
and the majority of RCTs are conducted by industry with
fewer investigator-initiated RCTs being performed [14]. At
the same time, many interventions are adopted into prac-
tice despite a poor evidence base [15]. In response to these
concerns, new approaches to RCTs have evolved that
attempt to address issues related to logistics, cost, and
relevance. These include RCT designs that utilize cohorts
[5] and routinely collected health data to facilitate recruit-
ment of participants and evaluate outcomes [16]. Rou-
tinely collected health data have been defined as data
collected without specific a priori research questions de-
veloped prior to using the data for research [17]. Sources
of routinely collected health data include registries [18,
19], electronic health records [20], and administrative da-
tabases [21]. Registries are set up for multiple purposes,
including research, but most typically transfer routinely
collected health data into a registry framework.
Cohorts and sources of routinely collected health data
may differ in how participants are enrolled, how data are
collected, and the degree of control that trial investigators
have in determining available outcome measures. Nonethe-
less, the methodological principles of RCTs that are embed-
ded in cohorts, registries, electronic health records, and
administrative databases are similar. In cohorts, a group of
individuals is gathered for the purpose of conducting re-
search. Cohort-embedded RCTs use observational cohorts
from which participants are subsequently enrolled in RCTs
[22] or cohorts that are designed from inception to provide
a framework for RCTs, as in the cohort multiple RCT
(cmRCT) design [5]. In the cmRCT design, patients enroll
in an observational cohort with regular outcome measure-
ment. For each RCT embedded in the cohort, a random se-
lection of RCT-eligible patients is contacted and offered
access to the intervention. Outcomes of patients randomly
allocated to the intervention group are compared to out-
comes of RCT-eligible patients not randomly allocated to
the intervention, who receive only usual care. Patients not
selected are not notified that they are involved in the RCT
usual care group, but their regularly collected cohort data
are used to evaluate outcomes [5, 23]. A key aspect of the
cmRCT design is that it replicates, as far as possible, con-
sent practices that would be applied in clinical care, where
patients are only notified about interventions that they can
actually access. The number of studies that have imple-
mented the cmRCT design is growing rapidly [24]. Exam-
ples include a recently completed RCT that involved
treatment of patients with depressive symptoms from the
UK South Yorkshire Cohort [25, 26]; a cohort of patients
with the rare disease scleroderma, which will support RCTs
of online rehabilitation, self-management, and psycho-
logical intervention programs [27]; a cohort for testing early
interventions to prevent severe mental illness [28]; and co-
horts of patients with cancer that will facilitate the conduct
of RCTs of an exercise program [29, 30], radiation therapy
[31, 32], and surgical interventions [33].
Disease or therapy registries are organized systems used
to routinely collect patients’ health information for clinical,
research, administration, or policy-related purposes [34].
Types of registries may include those that collect patient
characteristics and outcome data for all patients with a spe-
cific disease or condition, all patients in a geographical re-
gion, or all patients who are treated within a health care
service, or with a device or product. The type of data col-
lected in registries varies, but may include a combination of
data reported by patients, data recorded by health care pro-
viders, and data extracted from medical charts, institutional
or organizational databases, biomaterial, and imaging data
[35]. In registry-based RCTs, registries can be used for col-
lection of baseline characteristics, to identify eligible pa-
tients for a RCT, and as the source of outcome data; with
interactive methodology, they can also actively flag patients
for enrollment in a RCT as patient data are entered in the
registry [18, 19]. For example, the Swedish Coronary Angi-
ography and Angioplasty Registry was used to enroll pa-
tients with ST-elevation myocardial infarction for an RCT
of two different revascularization strategies [36]. Using the
same registry, RCTs on invasive diagnostic strategies in cor-
onary artery disease [37], different anticoagulation regimens
in acute coronary syndrome [38], and the effect of oxygen
therapy for patients with suspected myocardial infarction
[39] have been conducted. In the USA, an RCT comparing
post-procedure bleeding in percutaneous coronary inter-
vention via radial versus femoral access was conducted
within the National Institutes of Health National Cardio-
vascular Data Registry Cath-PCI Registry platform [40].
Electronic health records are electronic versions of a pa-
tient’s medical history in which data about all health care
episodes are routinely collected. They can provide a
method for comprehensive, often cross-institutional, lon-
gitudinal collection of patient health and health care data
[41]. Electronic health records have been used previously
to supplement data collection in RCTs [42], but are in-
creasingly used to identify patients for RCT participation,
assess them for eligibility, and assess outcomes using
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routinely collected data [43]. Electronic information sys-
tems in health care are becoming more common, and the
richness and completeness of electronic health research
databases have increased over time as more information is
being shared electronically between different parts of the
health-care system. An example of a RCT embedded in
electronic health records involved a comparison of simva-
statin and atorvastatin in patients with hypercholesterol-
emia and at high risk of cardiovascular disease [20].
Another example is an RCT that compared prophylactic
with deferred or non-use of antibiotics in patients with
mild to moderate exacerbation of chronic obstructive pul-
monary disease. Both were conducted in the UK using
routinely collected health records from general practi-
tioners [20]. Electronic health records can also form part
of an intervention to be tested in a clinical trial. For
example, one RCT tested an intervention to reduce anti-
biotic prescribing by feeding back personalized antibiotic
prescription data to primary care physicians [44]. Hence,
clinical trials can incorporate electronic health record
systems in multiple ways, at multiple stages and to very
different degrees.
Health system administrative databases include informa-
tion collected for administration or billing purposes (e.g.,
Medicare data in the USA). These data are routinely col-
lected during clinic, hospital, laboratory, or pharmacy
visits [45] and can provide easy and relatively inexpensive
access to large numbers of patients over expansive geo-
graphic regions. They are increasingly being used for epi-
demiological, effectiveness, and safety outcomes research
[45, 46]. As an example, in a cluster RCT that assessed
whether printed educational messages would increase the
use of thiazides as first-line medication for hypertension, a
Canadian provincial administrative database was used to
identify physicians with active general or family practices,
and patient administrative data were used to assess patient
outcomes [47]. Similar to electronic patient record sys-
tems, administrative databases can be used in RCTs at
multiple points from recruitment, to forming part of the
intervention, to data collection, and follow-up.
Because designs in which RCTs are embedded within
cohorts and routinely collected health data reflect rela-
tively recent innovations, published reports may not ad-
equately describe important aspects of these RCTs.
Reporting guidelines have been shown to improve the
quality of reports [48–52], but there is currently no
guideline for RCTs using cohorts and routinely col-
lected health data. The CONsolidated Standards of
Reporting Trials (CONSORT) reporting guideline,
which includes a 25-item checklist and flow diagram,
was developed to improve the quality of reporting of
parallel group RCTs [53]. In recent years, several exten-
sions of the CONSORT Statement have been developed
to encourage better reporting of other types of trial
designs, including, for instance, cluster trials [54], pilot
and feasibility trials [55], and pragmatic trials [56].
RCTs embedded in cohorts and routinely collected
health data share certain elements with “standard” RCTs
covered in the CONSORT statement, but there are also
aspects that differ and that may be important to report,
including, for example:
 How participants were identified or selected and
enrolled into the cohort or other external data
collection system
 Details of information that was provided or not
provided to participants about the potential for RCT
participation upon entry
 How ethical approval and consent were handled at
the observational data collection and RCT levels
 How RCT-eligible participants were identified and
allocated to RCT arms
 Description of the host data collection system and
markers of its quality or suitability for hosting a RCT
 Whether the availability of potential outcome
measures in the external data collection system may
have influenced the choice of RCT outcomes
 Whether definitions for data extraction were
determined a priori
 How supplemental information such as the study
protocol, raw data, or programming code can be
obtained
Thus, it is possible that some items in the general CON-
SORT checklist may not be appropriate for reporting on
RCTs using cohorts and routinely collected health data
and may require modification; there may be other items
that are essential for these types of RCTs, but are not in-
cluded in the standard CONSORT statement.
Given the relative novelty of RCTs using cohorts and
routinely collected health data, and the rapid pace at
which these designs are being adopted, an extension of
the CONSORT statement for these types of RCTs would
be a timely means of improving long-term reporting qual-
ity by setting standards early in the process of uptake. This
article describes the project plan for the development,
testing, and dissemination of an extension of a CONSORT
statement for RCTs conducted using cohorts and rou-
tinely collected health data.
Methods
The project has been registered with the Enhancing the
QUAlity and Transparency Of health Research (EQUA-
TOR) network [57]. This CONSORT extension will be
developed using a sequential approach, consistent with
previously published reporting guidelines created using
the EQUATOR Network’s guidance [58]. It will consist of
five phases. In phase 1, a research team and conceptual
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framework was established (completed in February 2018).
In phase 2, we will generate a long list of items for this
CONSORT extension from other key reporting guidelines
and via a systematic review. In phase 3, this list will be pri-
oritized using a Delphi exercise to assess appropriateness
and importance of each potential item and to generate a
shortlist of key items for consideration for inclusion. In
phase 4, the shortlist of items will serve as the basis for an
in-person consensus meeting to finalize a core set of items
for inclusion in the reporting guideline and checklist.
Phase 5 will involve write-up of the checklist and explan-
ation and elaboration document, dissemination, and im-
plementation. Figure 1 illustrates the planned process,
timeline, and integrated knowledge translation approach.
Phase 1: Research team and conceptual framework
To ensure project success, an organizational structure
with a Project Team, a Steering Committee, and a group
of key stakeholders has been defined.
Project team and steering committee
The project team is comprised of international experts in
RCT methodology, including members who have designed
and conducted RCTs using cohorts and routinely col-
lected health data; experts in the development of reporting
guidelines; experts in the conduct of systematic reviews;
and experts in statistical methods for health research. A
Steering Committee has been formed from team members
to oversee aspects of the project, including database
searching, study selection, data extraction, and data ana-
lysis, as well as the Delphi process, consensus meeting,
write-up of the resultant guideline documents, and the
implementation strategy. All team members will advise at
each project stage and will help draft and disseminate the
final guideline documents, help recruit stakeholders, and
aid dissemination of the reporting guideline.
Knowledge users and stakeholders
Key stakeholders who will be involved throughout the
process include guideline experts who disseminate guide-
lines to improve research (e.g., CONSORT, EQUATOR
Network, Society for Clinical Trials); funders, health ser-
vice decision-makers, journal editors; peer reviewers; trial-
ists; and a patient representative who has been involved in
engaging participants in RCTs embedded in a cohort.
Knowledge users will advise the project team and be in-
volved in dissemination and implementation.
Phase 2: Systematic review and generation of long list of
items
Preliminary “long list” generation
An initial “long list” of items will be formulated by review-
ing the original CONSORT 2010 statement items [53].
We will then identify items for adaptation and areas where
Fig. 1 Summary of process, timeline, and knowledge translation strategy
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additional items may be needed by reviewing the
Strengthening the Reporting of Observational Studies in
Epidemiology (STROBE) [59] and REporting of studies
Conducted using Observational Routinely collected Data
(RECORD) [17] statements. These statements are consid-
ered the most relevant to this project because of their
focus on reporting of observational studies and non-inter-
ventional studies using routinely collected health data.
Additional “long list” items identified will be identified by
our evidence review.
Registration of systematic review protocol
We will complete and publish our review protocol and
describe the rationale, hypothesis, and planned
methods according to the Preferred Reporting Items
for Systematic reviews and Meta-Analyses for Proto-
cols statement [60] and register it in PROSPERO
(International Prospective Register of Ongoing Sys-
tematic Reviews, http://www.crd.york.ac.uk/prospero).
Database searches
Typically, reviews conducted for the development of
reporting guidelines focus on articles about methods and
reporting. Because of the novelty of RCTs using cohorts
and routinely collected health data, we anticipate that we
will identify only a small number of methods and report-
ing articles; thus, we will also review primary RCT proto-
cols and reports of RCTs using these designs. We will
review primary RCT reports to attempt to identify areas
where reporting could be improved that may not be iden-
tified in the small number of existing methods articles that
we anticipate being able to review.
In separate searches, we will seek publications that de-
scribe aspects of methods or reporting or that describe
protocols or results from RCTs embedded in (1) cohorts;
(2) registries; (3) electronic health records; and (4) admin-
istrative databases. MEDLINE strategies for the searches
will be developed by a research librarian with input from
the team and peer reviewed using the Peer Review of the
Electronic Search Strategy standard [61]. The MEDLINE
strategy will then be adapted for the Cochrane Library
Methodology Register, which includes RCTs available up
to its last update in July 2012. Search strategies will com-
ply with Institute of Medicine standards and will not be
limited by language [62]. We will search for examples of
RCTs published in the last 10 years, which will allow us to
identify relatively recent reporting practices and focus on
challenging aspects of reporting. References of included
studies will be hand-searched for additional eligible stud-
ies, and experts in the field will be consulted.
Study selection
For each search, separately, the search results will be down-
loaded into the citation management database RefWorks,
and duplicate references will be removed. Following this,
references will be transferred into the systematic review
software DistillerSR®. A coding manual based on eligibility
criteria will be developed, and a pilot test of the coding
manual will be performed. Using the coding manual, we
will assess the eligibility of each publication through a two-
stage process. First, using a liberal accelerated approach
[63], we will screen titles and abstracts. Articles will be in-
cluded in the full-text review stage if one reviewer deems
them potentially eligible, but two reviewers will be needed
to exclude an article. Then a full-text review will be com-
pleted, with two investigators independently reviewing each
article. Disagreements after full-text review will be resolved
by consensus, with a third investigator consulted as neces-
sary. If the number of eligible articles identified is large, we
will select a random sample for review and data extraction.
Data extraction and verification
Eligible articles will be reviewed by the team to create
a “long list” of items as follows: for publications that
describe aspects of methods or reporting of RCTs con-
ducted using cohorts and routinely collected health
data, we will review the publications and identify ele-
ments of RCT design that are important to report. Po-
tential items should clarify or modify an existing
CONSORT 2010, STROBE, or RECORD item or if
they suggest a new element that should be reported as
a separate item. Elements will be checked for redun-
dancy between investigators, and if either investigator
or both deem it important to report, the item will be
included in the long list. For publications describing
protocols or results from RCTs using cohorts and rou-
tinely collected health data, two investigators will in-
dependently review publications to identify potential
modifications or clarifications of CONSORT 2010,
STROBE, and RECORD items and to identify potential
additional items. All identified items will be added to
the initial long list of items (with removal of dupli-
cates). Data will be collected in DistillerSR® using a
standardized data extraction form.
Long list verification
Members of the Steering Committee will assess each
item on the long list to exclude items that are clearly
not relevant, prior to starting the Delphi process. Each
assessor will independently evaluate the long-list of
items and will score potential items as “potentially
relevant” or “clearly not relevant.” Items that are
assessed as “clearly not relevant” by all members of
the Steering Committee will be removed. Items identi-
fied as potentially relevant by any of the members will
be included on the long list of items for evaluation in
the Delphi exercise.
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Phase 3: Delphi exercise and generation of “short list”
The “long list” created in phase 2 will serve as a base for a
three-round Delphi exercise that will be conducted using
established guidance for health care applications [64, 65].
This Delphi process has been used previously for similar
work in development of reporting guidelines [66].
The aim of this process is to achieve consensus on es-
sential items to be included in this CONSORT extension.
The Delphi process will be facilitated by team member
with experience in the Delphi process and in guideline
development. The Delphi participants will include all pro-
ject team members and knowledge users; additional par-
ticipants may be added if they are identified as potential
experts during the systematic review phase (e.g., authors
of published RCTs using cohorts and routinely collected
health data). There is no agreement on the minimum or
“ideal” panel size for Delphi studies, but we will aim for a
minimum of 20 participants, as this has been suggested to
provide stable results [67].
For each survey round, participants will be invited by
email, and they will have 2 weeks to complete each survey
online (with a reminder 1 week prior to survey closure).
All participants will be invited to each round of the survey
regardless of whether they completed the previous round.
Starting with the long list of potential items from
phase 2, during the survey, participants will be asked to
rank items based on how essential they are for report-
ing of RCTs embedded in cohorts and routinely
collected health data on a 1–5 Likert scale (1 = not es-
sential; 5 = essential). Likert scores will be categorized
as follows: 1–2 = low score (item should not be part of
CONSORT extension checklist), 3 = moderate (item
should be discussed), 4–5 = high score (item should be
part of CONSORT extension checklist). Participants
who rank items will also be able to provide comments
via an open-comment box. When any item is ranked in
the same category (i.e., low, moderate, or high) by more
than 2/3 of the Delphi respondents it will be deemed to
meet “consensus”; items that reach consensus in a Del-
phi round will be removed from the following Delphi
round [67]. Participants will also be asked to suggest
any additional potentially relevant items and provide a
brief rationale and clarification for the item.
The second round of the survey will include any items
that did not reach consensus in the first round and any
new items suggested by respondents in the first round. Re-
sults of the first round will be summarized (i.e., for each
item, the number of participants who have scored the item
and the distribution of scores, as well as a synthesis of
comments on the item) and will be fed back anonymously
to Delphi respondents. Respondents will be invited to re-
view their initial responses, considering the responses
from other Delphi respondents, and to re-score the item
on those tasks not achieving consensus.
As with the second round, the third round will involve
items that did not reach consensus in the first or second
round and any newly suggested items. In the third round,
the results from the second round will again be fed back to
all respondents, who will again be asked to rate each item.
Following the three rounds, the mean and median
scores for each item will be tabulated, and items will be
categorized as follows: no consensus (< 2/3 participants
rate the item in the category); consensus is reached for a
rating of moderate (3); consensus is reached for an item
rated as low (1, 2); consensus is reached for an item rated
as high (4, 5). Results of the Delphi exercise will be pre-
sented during the face-to-face meeting to help inform the
selection of checklist items.
Phase 4: Face-to-face consensus meeting and finalization
of list of essential items
A 2-day consensus meeting will be organized, and members
of the project team as well as key stakeholders will be invited
to participate. The main aim of this meeting will be to reach
consensus on items, informed by the Delphi survey, and to
arrive at a final list of essential items to report on RCTs
using cohorts and routinely collected health data. The
process will involve presentation of items by attendees with
key expertise followed by discussion. Items that reached
consensus in the Delphi survey will be considered first in
order to ratify those results. Each remaining item will then
be considered, and meeting participants will be given an op-
portunity to discuss each item, followed by anonymous scor-
ing by those at the consensus meeting. Meeting participants
will also be able to bring forward items excluded during the
Delphi process for reconsideration if they believe that a
clearer articulation or better explanation of the item might
alter the team’s conclusion. We will attempt to arrive at con-
sensus among meeting participants, and voting will be im-
plemented if no consensus can be reached.
It is anticipated that some items will be applicable for all
types of RCTs conducted via cohorts and routinely col-
lected health data, whereas some may not apply to all de-
signs, and this will be clarified. Additional aims of this
meeting include reviewing the CONSORT flow diagram to
determine if any revisions are necessary, discussing an out-
line of the checklist and elaboration-explanation document,
and planning the publication and dissemination strategy.
Phase 5: Knowledge translation
Checklist pilot, revision of checklist based on feedback, and
guidance statements
After finalizing the checklist at the consensus meeting, the
team will apply the checklist to a random sample of pub-
lished reports that describe results from relevant RCTs in
order to identify practical challenges and to inform writing
of the statement and explanation and elaboration. The
piloting phase will include testing by members of the
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research team, other trialists who will be invited to pilot
the checklist, and graduate students from participating in-
stitutions who are enrolled in trial-related courses.
Steering committee members will lead the writing of the
final version of the checklist and the associated guidance
statement. This will be circulated to the broader project
team for input prior to submission for publication. Mem-
bers of the steering committee will also lead the writing of
the explanation and elaboration document, which will serve
as a “user guide” for the checklist and will include an
item-by-item explanation plus examples of good reporting
practice to aid interpretation. This explanatory document
will also be circulated to the broader research team for in-
put prior to submission for publication.
Baseline assessment
A study with the aim to provide a baseline assessment of
completeness of reporting of RCTs using cohorts and
routinely collected health data prior to publication of
the reporting guideline, as measured by this CONSORT
extension checklist, will be conducted in order to track
change in reporting quality over time.
Dissemination
A detailed knowledge transfer plan will be developed at
the face-to-face meeting in phase 4 using strategies that
have been successfully implemented by EQUATOR for
similar reporting guidelines. Multiple simultaneous publi-
cations of the CONSORT extension checklist and the ex-
planation and elaboration document will be sought in
journals that may publish RCTs that use cohorts and rou-
tinely collected health data. Further dissemination will in-
clude presentation at major medical, health care policy
and trial-related conferences, presentation at editorial for-
ums and to major funders of RCTs, publication on the
CONSORT and EQUATOR websites, and dissemination
through relevant social media channels.
Implementation
Activities aimed at user training and encouraging uptake of
this CONSORT extension will include implementation
through strategies that have been used successfully previ-
ously in similar projects by knowledge user partners from
CONSORT and EQUATOR (e.g., workshops and lectures),
guided by members of the project team. We will also reach
out to journal editors to encourage endorsement and im-
plementation of this CONSORT extension for RCTs using
cohorts and routinely collected health data. This could be
in the form of including this CONSORT extension in the
instructions for authors as a source of guidance and sub-
mission of the CONSORT extension checklist with the
manuscript. Other endorsement and implementation strat-
egies, as well as a strategy for evaluating effectiveness will
be discussed during the face-to-face meeting.
Discussion
Development of this CONSORT extension for RCTs con-
ducted using cohorts and routinely collected health data is
being done with the goals of contributing to transparent
reporting of these types of RCTs, reducing research waste,
and facilitating their reproducibility.
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